Multiple CNS Therapies Advancing
An advanced pipeline that’s closer to where you live than you might expect.
cvn424
(Adjunctive & monotherapy)
cvn766
(Negative and cognitive symptoms)
CVN293
(Disease modification)
CVN398
(Disease modification)
Target-18
(Disease modification)
Target-26
(Disease modification)
Multiple Early Targets
The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreSolengepras
(CVN424)
Target:
GPR6
Indication:
Parkinson’s disease
Highlight:
Significant reduction (1.59-hours) in OFF time versus placebo without dopaminergic side effects
Solengepras (CVN424) is a first-in-class non-dopamine therapy that selectively modulates GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect (striatopallidal) pathway, important in the control of movement. Solengepras (CVN424) shows promise in improving both motor and quality of life/non-motor symptoms of Parkinson's disease and may also have disease-delaying effects.
Learn morePhase 2 Monotherapy Study
Click here to learn more or to see if you are eligible for participation in the study
CVN766
Target:
Orexin 1 receptor
Indication:
Psychiatric conditions
Highlight:
Safe and well tolerated with no signs of somnolence
CVN766 is a potent and highly selective antagonist of the Ox1R compared to Ox2R (>1000 fold). Ox1R has genetic links to domains of psychiatric disorders and is expressed in areas of the brain important for regulating emotions, fear, anxiety and motivation. CVN766 has demonstrated efficacy in multiple preclinical models and may benefit a variety of psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome.
Learn moreCVN293
Target:
KCNK13
Indication:
ALS/Alzheimer's disease
Highlight:
Lower peripheral expression allows targeting CNS inflammation while sparing peripheral immune system
CVN293 targets KCNK13, a microglia specifically expressed potassium channel. KCNK13 inhibition will reduce K+ efflux and inflammasome formation in microglia, attenuate aberrant neuroinflammation and slow neurodegeneration. Cerevance is currently conducting a Phase 1 study to demonstrate safety and tolerability with topline data expected Q3 2024.
Target 20
Target:
GPR6 - an inverse agonist for parkinson’s disease
Indication:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreCVN424
Target:
GPR6 - an inverse agonist for parkinson’s disease
Indication:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn morePatient Resources:
We encourage connecting with organizations that focus on CNS diseases. Below you’ll find learning opportunities, ideas on ways to care for and support those with diseases caused by CNS disorders as well as how to become a part of important research.